During the past decade, MaculaCare conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 9 clinical trials were completed, i.e. on average, 64.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MaculaCare" #1 sponsor was "Jaeb Center for Health Research" with 10 trials, followed by "OccuLogix" with 3 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "ThromboGenics" with 2 trials sponsored and "Alimera Sciences" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MaculaCare" #1 collaborator was "National Eye Institute (NEI)" with 8 trials as a collaborator, "National Institutes of Health (NIH)" with 6 trials as a collaborator, "Regeneron Pharmaceuticals" with 4 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 2 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "MaculaCare" are "Diabetic Macular Edema" (7 trials), "Diabetic Retinopathy" (3 trials), "Geographic Atrophy" (2 trials), "Macular Degeneration" (2 trials) and ""Wet" Age-Related Macular Degeneration" (1 trials). Many other conditions were trialed in "MaculaCare" in a lesser frequency.

Most popular intervention types in "MaculaCare" are "Drug" (14 trials), "Device" (5 trials), "Procedure" (5 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Aflibercept" (2 trials), "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials) and "Prompt aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "MaculaCare" are 22 trials for "All" genders.

Currently, there are NaN active trials in "MaculaCare". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in MaculaCare, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in MaculaCare, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".